Fatty Liver (Hepatic Steatosis)

What is Fatty Liver?

Fatty liver, or hepatic steatosis, refers to accumulation of excess fat within liver cells (hepatocytes). It is one of the most common liver disorders and is often reversible in early stages.

Types of Fatty Liver

• Non-Alcoholic Fatty Liver Disease (NAFLD)

  • Most common type

  • Occurs independent of alcohol consumption 

  • Strongly associated with:

  • Obesity

  • Insulin resistance / Type 2 diabetes

  • Dyslipidemia

  • Metabolic syndrome

  • Spectrum:

  • Simple steatosis → benign

  • Non-alcoholic steatohepatitis (NASH) → inflammation + hepatocyte injury → risk of fibrosis

• Alcoholic Fatty Liver Disease

  • Caused by chronic excessive alcohol intake 

  • Earliest stage of alcohol-related liver disease

  • May progress to:

  • Alcoholic hepatitis

  • Cirrhosis

Causes and Risk Factors

• NAFLD

  • Obesity (especially central obesity)

  • Insulin resistance / Type 2 diabetes

  • Hypertension

  • Hyperlipidemia

  • Metabolic syndrome

  • Rapid weight loss

  • Certain drugs (e.g., steroids, amiodarone, methotrexate)

  • Genetic predisposition

• Alcoholic Fatty Liver

  • Dose- and duration-dependent alcohol toxicity

Symptoms

• Most patients are asymptomatic, especially early.

• When present:

• Fatigue

• Right upper abdominal discomfort

• Mild hepatomegaly

• Unexplained weight loss (occasionally)

Advanced disease:

• Jaundice

• Signs of chronic liver disease

Diagnosis

• Laboratory

  • Liver enzymes (ALT, AST)

  • Lipid profile

  • Blood glucose / HbA1c

• Imaging

  • Ultrasound (USG): first-line

  • CT / MRI: better quantification

  • Fibroscan (elastography): fibrosis assessment

• Liver Biopsy

  • Gold standard (rarely required)

  • Indicated when diagnosis or staging is uncertain

What to Do if USG Shows Fatty Liver

• Clinical evaluation 

  • Detailed history (alcohol, drugs, metabolic risk factors)

• Assess severity 

  • LFTs, fibrosis scoring (FIB-4, NAFLD fibrosis score)

  • Fibroscan if indicated

• Identify cause 

  • NAFLD vs alcohol-related

• Screen comorbidities 

  • Diabetes

  • Dyslipidemia

  • Hypertension

Management

Lifestyle Modification (Cornerstone)

• Weight Loss

  • Target: 5–10% body weight reduction 

  • Improves steatosis, inflammation, and fibrosis

• Diet

  • Calorie restriction

  • Low refined carbohydrates and sugars

  • High fiber, whole foods

  • Healthy fats (MUFA/PUFA)

• Exercise

  • ≥150 minutes/week moderate intensity

  • Improves insulin sensitivity independent of weight loss

• Alcohol

  • Complete abstinence (essential in alcoholic liver disease)

  • Avoid even moderate intake in NAFLD with fibrosis

• Control Comorbidities

  • Tight glycemic control

  • Lipid management

  • Blood pressure control

Pharmacotherapy (Selective)

• No universal drug approved for NAFLD

• Consider in NASH with fibrosis:

• Pioglitazone

• Vitamin E (non-diabetic patients)

• Emerging therapies under evaluation

Is Fatty Liver a Lifestyle Disease?

Yes—NAFLD is largely a lifestyle-related metabolic disease.

Key contributors:

• Sedentary behavior

• High-calorie, high-sugar diet

• Obesity

• Metabolic syndrome

• Alcoholic fatty liver is also lifestyle-related via alcohol intake.

Can It Be Cured?

Reversible Stages

Simple steatosis: often completely reversible with sustained lifestyle changes

Advanced Stages

NASH and fibrosis:

Improvement possible

Complete reversal less predictable

Alcoholic Fatty Liver

Reversible if alcohol stopped early

Dietary Recommendations (Evidence-Based)

Recommended

• Vegetables, fruits (low glycemic index)

• Whole grains

• Lean protein (fish, poultry, legumes)

• Nuts, seeds

• Olive oil

Avoid / Limit

• Added sugars (especially fructose)

• Refined carbohydrates

• Processed foods

• Saturated and trans fats

• Sugary beverages

Other Key Points

• Portion control

• Adequate hydration

• Avoid crash dieting

Prognosis

• Early stages: excellent with intervention 

• Untreated disease may progress to:

• Cirrhosis

• Liver failure

• Hepatocellular carcinoma

Key Clinical Takeaways

• Fatty liver is common, often silent, and reversible early 

• Lifestyle intervention is the primary treatment 

• Risk stratification for fibrosis is essential

• Long-term monitoring is required